Abstract
Statins are a diverse group of drugs, which share the ability to inhibit HMG CoA reductase and thereby the conversion of acetoacetyl CoA to mevalonate, the rate-limiting step in cholesterol biosynthesis. By inhibiting mevalonate production statins inhibit the pathway leading to the generation of farnesylpyrophosphate and geranylgeranyl pyrophosphate, two pyrophosphates that are critical for the induction of a variety of signal transduction pathways, which promote a cascade of events leading to endothelial dysfunction, inflammation, proliferation, apoptosis and other effects important for atherogenesis. Even though statins share a common mode of action they differ by several features like chemical structure, affinity towards HMG CoA reductase and their relative lipophilicity. These features translate into marked differences in LDL cholesterol lowering efficacy, pharmacokinetic properties and differences in lipophilicity associated with different tissue affinity and penetration. Rosuvastatin and atorvastatin produce the greatest percentage change in LDL cholesterol. Fluvastatin and pravastatin are less prone to drug interactions, because they are not metabolized through the CYP450 3A4 system. The hydrophilic pravastatin does not inhibit proliferation and migration of vascular smooth muscle cells. Data from clinical trials with statins suggest that the efficacy in LDL cholesterol lowering plays the overriding role in cardiovascular event reduction.
Keywords: HMG CoA reductase inhibitors, pleiotropic effects, cardiovascular disease prevention, LDL cholesterol lowering, lipids, statins
Current Drug Therapy
Title: Statins: Are They All the Same?
Volume: 1 Issue: 2
Author(s): Walter F. Riesen
Affiliation:
Keywords: HMG CoA reductase inhibitors, pleiotropic effects, cardiovascular disease prevention, LDL cholesterol lowering, lipids, statins
Abstract: Statins are a diverse group of drugs, which share the ability to inhibit HMG CoA reductase and thereby the conversion of acetoacetyl CoA to mevalonate, the rate-limiting step in cholesterol biosynthesis. By inhibiting mevalonate production statins inhibit the pathway leading to the generation of farnesylpyrophosphate and geranylgeranyl pyrophosphate, two pyrophosphates that are critical for the induction of a variety of signal transduction pathways, which promote a cascade of events leading to endothelial dysfunction, inflammation, proliferation, apoptosis and other effects important for atherogenesis. Even though statins share a common mode of action they differ by several features like chemical structure, affinity towards HMG CoA reductase and their relative lipophilicity. These features translate into marked differences in LDL cholesterol lowering efficacy, pharmacokinetic properties and differences in lipophilicity associated with different tissue affinity and penetration. Rosuvastatin and atorvastatin produce the greatest percentage change in LDL cholesterol. Fluvastatin and pravastatin are less prone to drug interactions, because they are not metabolized through the CYP450 3A4 system. The hydrophilic pravastatin does not inhibit proliferation and migration of vascular smooth muscle cells. Data from clinical trials with statins suggest that the efficacy in LDL cholesterol lowering plays the overriding role in cardiovascular event reduction.
Export Options
About this article
Cite this article as:
Riesen F. Walter, Statins: Are They All the Same?, Current Drug Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157488506776930969
DOI https://dx.doi.org/10.2174/157488506776930969 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiac Workup of Ischemic Stroke
Current Cardiology Reviews Editorial: [Hot Topic: Pharmaceutical Kinetics and Toxicological Effects of Nanosystems and Nanomaterials for Biomedical Applications]
Current Drug Metabolism Hybrid Therapy in the Management of Atrial Fibrillation
Current Cardiology Reviews Comparative Molecular Characterization to Reveal Surface Behaviour of Non-proteolytic Bromelain Mutants
Current Pharmaceutical Biotechnology Biologically Responsive Nanosystems Targeting Cardiovascular Diseases
Current Drug Delivery Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?
Current Vascular Pharmacology Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Central Nervous System Agents in Medicinal Chemistry Pre-Clinical and Clinical Evaluation of Nuclear Tracers for the Molecular Imaging of Vulnerable Atherosclerosis: An Overview
Current Medicinal Chemistry Pharmacogenetic Applications of the Post Genomic Era
Current Pharmaceutical Biotechnology Oxidative Stress-Induced Ischemic Heart Disease: Protection by Antioxidants
Current Medicinal Chemistry Mass Spectrometry-Based Metabolic Profiling
Current Metabolomics Anti-Biofilm Strategies and the Need for Innovations in Wound Care
Recent Patents on Anti-Infective Drug Discovery Role of Advanced Glycation End Products (AGEs) in Thrombogenic Abnormalities in Diabetes
Current Neurovascular Research Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology Enhancing Cardiovascular Dynamics by Inhibition of Thrombospondin- 1/CD47 Signaling
Current Drug Targets Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Current Molecular Medicine A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases
Current Topics in Medicinal Chemistry The Role of Cellular Senescence During Vascular Calcification: A Key Paradigm in Aging Research
Current Aging Science Silent Partner in Blood Vessel Homeostasis? Pervasive Role of Nitric Oxide in Vascular Disease
Current Hypertension Reviews Clozapine Safety, 35 Years Later
Current Drug Safety